High-quality evidence generated by appropriately powered and controlled trials is needed to advance care for patients with coronavirus disease 2019 (COVID-19) and those who are susceptible to it.1,2 In the midst of the COVID-19 pandemic, multiple similar therapeutic trials are being conducted in parallel, potentially reducing participant accrual across trials. In this systematic review, we characterize the landscape of current COVID-19 trials to better quantify these potential issues.
Institutional review board approval of this study was waived because it exclusively used publicly available data without any protected health information. Screening and trial selection adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.3